Journal
MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume 446, Issue 1-2, Pages 91-103Publisher
SPRINGER
DOI: 10.1007/s11010-018-3276-1
Keywords
Ischemia-reperfusion injury; Eplerenone; PI3K/Akt pathway; GSK-3 beta; Diabetes
Categories
Funding
- Early Career Research Award Scheme of Science and Engineering Research Board (SERB), Department of Science and Technology, New Delhi, India [ECR/2016/001243]
- United Arab Emirates University, United Arab Emirates
Ask authors/readers for more resources
We investigated the eplerenone-induced, PI3K/Akt- and GSK-3 beta-mediated cardioprotection against ischemia/reperfusion (I/R) injury in diabetic rats. The study groups comprising diabetic rats were treated for 14 days with 150 mg/kg/day eplerenone orally and 1 mg/kg wortmannin (PI3K/Akt antagonist) intraperitoneally with eplerenone. On the 15th day, the rats were exposed to I/R injury by 20-min occlusion of the left anterior descending coronary artery followed by 30 min of reperfusion. The hearts were processed for biochemical, molecular, and histological investigations. The I/R injury in diabetic rats inflicted a significant rise in the oxidative stress and apoptosis along with a decrease in the arterial and ventricular function and the expressions of PI3K/Akt and GSK-3 beta proteins. Eplerenone pretreatment reduced the arterial pressure, cardiac inotropy, and lusitropy. It significantly reduced apoptosis and cardiac injury markers. The histology revealed cardioprotection in eplerenone-treated rats. Eplerenone up-regulated the PI3K/Akt and reduced the GSK-3 beta expression. The group receiving wortmannin with eplerenone was deprived eplerenone-induced cardioprotection. Our results reveal the eplerenone-induced cardioprotection against I/R injury in diabetic rats and substantiate the involvement of PI3K/Akt and GSK-3 beta pathways in its efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available